FILTER
LATEST INTERVIEWS
James Wallbank
MANAGING PARTNER, IBAERA CAPITAL
Ibaera Capital explains its investment strategy as it opens a new and larger fund.
Dolores Biamou
MINING PROJECTS DIRECTOR AFRICA, BOLLORÉ LOGISTICS
Bolloré Logistics explains how it maintained supply chain continuity throughout the lock-down period.
Nicolas Balesme
MANAGING PARTNER AND O&G LEADER, DELOITTE GABON & CENTRAL AFRICA
Deloitte Gabon explains the current regulatory environment for the country’s oil and gas industry.
Ricardo do Amaral
GENERAL MANAGER, OCTOMAR
Octomar explains how the company has navigated this difficult year and its plans to expand to partake in Mozambique’s exciting offshore developments.
Tidiane Barry
PRESIDENT, BURKINA FASO CHAMBER OF MINES
The Burkina Faso Chamber of Mines provides an overview of the country’s mining sector.
Oscar Gonzalez Rocha
PRESIDENT & CEO, SOUTHERN COPPER
Southern Copper outlines its handling of the pandemic and its ambitions in Peru.
Rajiv Anand
FOUNDER & CEO, QUARTIC AI
"Much of the focus of tech development has been for people in IT and data science. This creates a big barrier to adoption for chemists, biologists or chemical engineers, it is unsustainable. Overcoming those two barriers is the inspiration behind Quartic.ai."
Ignacio Bustamante
PRESIDENT & CEO, HOCHSCHILD MINING
Hochschild Mining has a busy last quarter ahead with ambitious drilling programs for its mines in Peru and the America’s more generally.
Sergio Marcondes & Emilio Nager
GENERAL MANAGER & COMMERCIAL MANAGER INTERNATIONAL MARKETS, BRASKEM ARGENTINA
Braskem began activities in Argentina in 2006 and is determined to remain for the long term.
Gonzalo Díaz Pró
GENERAL MANAGER, FERREYROS S.A.
Ferreyros represents CAT machinery in Peru and comments on current business conditions.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
